$Pfizer (PFE.US)$ According to Zhittong Finance, Pfizer anno...

According to Zhittong Finance, Pfizer announced on Tuesday that Mikael Dolsten, its Chief Scientific Officer and R&D President, will leave the company after more than 15 years of service. The New York-based pharmaceutical giant said it would launch a months-long external recruitment program to identify a new Chief Scientific Officer, a move expected to last until early next year. The company said, "Dolsten will assist in job search and continue in his current role until his successor is in place and any necessary transition is complete."

Dolsten joined Pfizer in 2009 after its acquisition of Wyeth, where he was the Global R&D President. During his tenure at Pfizer, the company obtained approvals for more than 35 drugs and vaccines, including its most famous product - the Comirnaty COVID-19 vaccine developed in partnership with global biotechnology company BioNTech.